What is the recommended treatment for a gastric ulcer?

Treatment for Gastric Ulcer

All patients with gastric ulcers should be tested for H. pylori infection and receive eradication therapy if positive, combined with proton pump inhibitor (PPI) therapy for 6-8 weeks, while discontinuing NSAIDs if possible. 1

Initial Diagnostic Approach

Test all gastric ulcer patients for H. pylori infection using either urea breath test (sensitivity 88-95%, specificity 95-100%) or stool antigen testing (sensitivity 94%, specificity 92%). 1 In patients undergoing endoscopy, tissue biopsy can confirm infection. 1 If initial testing during acute bleeding is negative, repeat testing after the acute phase as false-negatives are common in this setting. 2, 3

Obtain a detailed medication history focusing on NSAID use, aspirin, anticoagulants, and antiplatelet agents, as these are the primary non-infectious causes of gastric ulcers. 1, 4

Treatment Algorithm Based on Etiology

H. pylori-Positive Patients (with or without NSAIDs)

First-line eradication therapy: Standard triple therapy for 14 days if local clarithromycin resistance is low 1:

• PPI standard dose twice daily
• Clarithromycin 500 mg twice daily
• Amoxicillin 1000 mg twice daily (or Metronidazole 500 mg twice daily if penicillin allergic)

Alternative first-line in areas with high clarithromycin resistance: Sequential therapy for 10 days 1:

• Days 1-5: PPI twice daily + Amoxicillin 1000 mg twice daily
• Days 6-10: PPI twice daily + Clarithromycin 500 mg twice daily + Metronidazole 500 mg twice daily

Second-line therapy if first-line fails: Levofloxacin-based triple therapy for 10 days 1:

• PPI standard dose twice daily
• Levofloxacin 500 mg once daily (or 250 mg twice daily)
• Amoxicillin 1000 mg twice daily

Consider P-CAB (vonoprazan) instead of PPI for H. pylori eradication regimens, as it achieves superior eradication rates (92% vs 80% with PPIs), particularly in clarithromycin-resistant infections (66-70% vs 32%). 5 The 2022 Maastricht VI/Florence Consensus endorsed P-CAB-based regimens as superior or non-inferior to PPI-based triple therapy. 5

NSAID-Associated Ulcers (H. pylori-negative)

Discontinue NSAIDs immediately if possible. 6, 7 If NSAIDs cannot be stopped, treat with PPIs for 6-8 weeks. 1, 6

For patients requiring continued NSAID therapy:

• Prescribe PPI co-therapy (reduces ulcer risk by approximately 50%) 4
• Consider switching to celecoxib (COX-2 selective inhibitor) with PPI 8, 4
• Vonoprazan 10-20 mg is non-inferior to lansoprazole 15 mg for preventing ulcer recurrence in high-risk patients 5

H. pylori-Negative, Non-NSAID Ulcers (Idiopathic)

Treat with PPI therapy for 6-8 weeks. 8, 6 These patients require careful endoscopic follow-up to exclude malignancy (gastric adenocarcinoma, lymphoma) or non-peptic causes (Crohn's disease). 6 Mandatory endoscopic re-evaluation to confirm complete healing is essential in this population. 6

Acid Suppression Therapy

Standard PPI therapy: Continue for 6-8 weeks after ulcer diagnosis. 1 Long-term maintenance PPI is not recommended unless the patient has ongoing NSAID use or recurrent ulcers. 1

For bleeding ulcers with high-risk stigmata after successful endoscopic hemostasis: Administer high-dose intravenous PPI (80 mg bolus followed by 8 mg/hour continuous infusion for 72 hours), then transition to oral PPI twice daily for 14 days, followed by once daily. 1, 3

P-CABs are generally not recommended as first-line therapy for uncomplicated peptic ulcer disease given higher costs and limited availability, though they are non-inferior to PPIs for ulcer healing (94% vs 94% at 8 weeks). 5 Reserve P-CABs for PPI treatment failures. 5

Critical Management Points

For bleeding gastric ulcers: Endoscopy is the first-line diagnostic and therapeutic intervention in hemodynamically stable patients. 9, 3 Combination endoscopic therapy (thermocoagulation or clips plus epinephrine injection) is superior to epinephrine injection alone. 3

Confirm H. pylori eradication 4-6 weeks after completing antibiotic therapy using urea breath test or stool antigen testing. 2, 3 Eradication reduces rebleeding rates from 26% to near zero. 1

Avoid histamine-2 receptor antagonists (H2RAs) as they are inferior to PPIs for ulcer healing and prevention of complications. 3

Common Pitfalls

Do not apply empirical H. pylori eradication therapy to all patients without confirming infection status, as regional prevalence varies (20-50% in bleeding ulcers). 1 Test-directed therapy is more cost-effective. 1

Do not use P-CABs as routine first-line therapy for uncomplicated ulcers given current costs and availability, despite non-inferior efficacy. 5

Recognize that negative H. pylori tests during acute bleeding may be false-negatives due to decreased bacterial load; repeat testing after resolution is essential. 2, 3

In patients with refractory ulcers despite adequate therapy, rule out Zollinger-Ellison syndrome, malignancy, Crohn's disease, medication non-compliance, and continued NSAID use. 9, 6